Roche Holding AG
RHHBYNext catalyst
Giredestrant
Adjuvant ER-positive, HER2-negative stage I-III breast cancer
Get an email about RHHBY's next catalysts
Track Roche Holding (RHHBY) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 64 more upcoming events in our data (Phase 3 readout, Phase 2 readout, regulatory event and more).See the timeline
67 upcoming, 5 past
Risdiplam Phase 3 Est. Readout (MANATEE)
Estimated primary completion for Risdiplam trial (NCT05115110) in Spinal Muscular Atrophy (SMA). Topline data typically follows completion by weeks to months.
SourceAfimkibart Phase 3 Est. Readout (Ametrine-2)
Estimated primary completion for Afimkibart trial (NCT06588855) in Moderately to Severely Active Ulcerative Colitis. Topline data typically follows completion by weeks to months.
SourceAtezolizumab Phase 2 Est. Readout (PANDA)
Estimated primary completion for Atezolizumab trial (NCT03448835) in Stomach Cancer. Topline data typically follows completion by weeks to months.
SourceRegulatory
RHHBY, VTRS, and IRD face key FDA drug rulings in October 2026, while MRK withdraws its application.
SourceInavolisib Phase 3 Est. Readout (INAVO121)
Primary completion for Inavolisib trial (NCT05646862) in Breast Cancer
SourceFDA PDUFA Date Obinutuzumab (Gazyva)
For Primary membranous nephropathy. sBLA, Priority Review; company says by November 2026, no exact day. Verified against the company announcement on 2026-10-16.
SourceRO7269162 Phase 2 Est. Readout
Primary completion for RO7269162 trial (NCT06402838) in Alzheimer's Disease
SourceFDA PDUFA Date giredestrant (adjuvant)
For Adjuvant ER-positive, HER2-negative stage I-III breast cancer. NDA, Priority Review. Verified against the company announcement on 2026-10-16.
SourceUpcoming FDA decisions
How RHHBY's past catalysts played out
Market Overview
Stock performance and key metrics
Pertuzumab IV
Early Breast Cancer
Afimkibart
Crohns Disease
tocilizumab [RoActemra/Actemra]
Rheumatoid Arthritis
Vitamin Supplements
Hematological Malignancies
AT1 blocker candesartan
Breast Cancer
Methoxy polyethylene glycol-epoetin beta (C.E.R.A.)
Anemia
Mircera
Anemia
Saquinavir
HIV Infections
rituximab [MabThera/Rituxan]
Rheumatoid Arthritis
liposomal doxorubicin
Ovarian Cancer
Omalizumab
Nasal Polyps
csDMARDs
Rheumatoid Arthritis
tocilizumab
Rheumatoid Arthritis
ritonavir
HIV Infections
Etrolizumab
Crohn Disease
Epoetin beta
Anemia
rituximab (Mabthera®)
Warm Autoimmune Hemolytic Anemia
Lurbinectedin
Small-Cell Lung Cancer
taspoglutide
Diabetes Mellitus Type 2
Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody
Triple-Negative Breast Cancer
Ibandronate
Post-Menopausal Osteoporosis
Entrectinib
Solid Tumors
Methoxy Polyethylene Glycol-Epoetin Beta
Anemia
mycophenolate mofetil (CellCept)
Myasthenia Gravis, Generalized
Onartuzumab
Glioblastoma
Pirfenidone
Lung Diseases, Interstitial
Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody
Carcinoma, Non-Squamous Non-Small Cell Lung
Fixed Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Use (PH FDC SC)
Early Breast Cancer
Trastuzumab IV
HER2-positive Early Breast Cancer
Other Combination Anti-Cancer Therapies
Solid Tumors
Valganciclovir
Cytomegalovirus Infections
Filgrastim
Triple-negative Breast Cancer
Herceptin
Breast Cancer
Trastuzumab Emtansine
Breast Cancer
Fenebrutinib
Relapsing Multiple Sclerosis
Glofitamab
Diffuse Large B-cell Lymphoma
Alectinib
Non-Small Cell Lung Cancer
Peginterferon alfa-2a
Carcinoma, Hepatocellular
Cladribine
Lymphocytic Leukemia, Chronic
ibandronate [Bonviva/Boniva]
Post-Menopausal Osteopenia
Trontinemab
Alzheimers Disease
aleglitazar
Diabetes Mellitus Type 2
Alectnib
Carcinoma, Non-Small-Cell Lung
Chemotherapy
Non-Small Cell Lung Cancer
Inavolisib
Breast Cancer
Leucovorin (LV)
Colorectal Cancer
CHOP
Lymphoma, Large B-Cell, Diffuse
RO4917838
Schizophrenia
Baseline Treatment
Neuromyelitis Optica (NMO)
Acetaminophen/Paracetamol
Systemic Lupus Erythematosus
Phesgo
Locally Advanced or Metastatic Breast Cancer
Fludarabine Phosphate
Chronic Lymphocytic Leukemia
Ribociclib
Breast Cancer
methoxy polyethylene glycol-epoetin beta [C.E.R.A.]
Anemia
Ortho-Novum® 1/35
Rheumatoid Arthritis
PEGASYS
Hepatitis C, Chronic
RO7771950
HER2-positive Breast Cancer
aleglitazar+metformin
Diabetes Mellitus Type 2
dalcetrapib
Coronary Heart Disease
Tiragolumab and Atezolizumab
Cancer
Cobimetinib
Melanoma
DMARDs
Rheumatoid Arthritis
MabThera/Rituxan
Rheumatoid Arthritis
RO7234292
Huntingtons Disease
Crovalimab
Atypical Hemolytic Uremic Syndrome
Entecavir
Pediatric Immuno-Tolerant Chronic Hepatitis B
Mosunetuzumab
Non-Hodgkin Lymphoma
Prasinezumab
Parkinsons Disease
methoxy polyethylene glycol-epoetin beta (Mircera)
Anemia
Dalcetrapib (RO4607381)
Coronary Heart Disease
FEC Chemotherapy
Breast Cancer
Darbepoetin alfa
Anemia
Interferon beta-1a
Relapsing Multiple Sclerosis
Ibandronate, Capecitabine
Breast Cancer
Bevacizumab + Pemetrexed + Carboplatin
Non-squamous Non-small Cell Lung Cancer
Bevacizumab + Pemetrexed
Non-squamous Non-small Cell Lung Cancer
RO0503821 (1x/4 Weeks)
Anemia
Evidence-based medical care for Acute Coronary Syndrome
Coronary Heart Disease
Tiragolumab
Small Cell Lung Cancer
methoxy polyethylene glycol-epoetin beta [RO0503821, Mircera]
Anemia
methylprednisolone
Rheumatoid Arthritis
Vamikibart
Diabetic Macular Edema
Factor VIII (FVIII)
Hemophilia A
Pralsetinib
RET-fusion Non Small Cell Lung Cancer
Anti-VEGF Therapy
Neovascular Age-related Macular Degeneration
epoetin alfa or beta
Anemia
5-Fluorouracil, Folic acid, Capecitabine; Bevacizumab
Colorectal Neoplasms
Zidovudine
HIV Infections
Remdesivir
COVID-19 Pneumonia
Polatuzumab Vedotin
Non-Hodgkin's Lymphoma
r-HuEPO
Anemia
Fingolimod
Relapsing-Remitting Multiple Sclerosis
Teriflunomide
Relapsing Multiple Sclerosis
Sefaxersen (RO7434656)
Primary IgA Nephropathy
Standard DMARDs (Disease Modifying Anti Rheumatic Drugs)
Rheumatoid Arthritis
Tocilizumab (TCZ)
Rheumatoid Arthritis
Valganciclovir CMV Prophylaxis
Cytomegalovirus Infections
Herceptin IV
Breast Cancer
Neo-adjuvant chemotherapy
Breast Cancer
Enfuvirtide
HIV Infections
Pertuzumab
Breast Cancer
Taxane-based chemotherapy
Breast Cancer
Cyclosporine
Renal Transplantation
23-PPV
Multiple Sclerosis, Relapsing-Remitting
FAP IL2V
Cancer
Alimta or Taxotere
Non-Small Cell Lung Cancer
Oxaliplatin
Colorectal Cancer
Non-steroidal anti-inflammatory drugs (NSAIDs)
Juvenile Idiopathic Arthritis
chlorambucil
Lymphocytic Leukemia, Chronic
5-Fluoruracil
Gastric Cancer
Giredestrant
Endometrial Cancer
Oseltamivir IV
Influenza
Interferon alfa 2a
Renal Cell Cancer
Disease-modifying anti-rheumatic drugs
Rheumatoid Arthritis
Becavizumab
Hepatocellular Carcinoma
Azathioprine
Rheumatoid Arthritis
Crizotinib
Neoplasms
Bitopertin
Beta-Thalassemia
Pegylated Interferon Alfa-2a
Chronic Myelogenous Leukemia
Divarasib
Non-Small Cell Lung Cancer
Rituximab SC
Non-Hodgkin's Lymphoma
Optimized background antiretroviral regimen (OB)
HIV Infections
Permitted DMARDs
Rheumatoid Arthritis
Telmisartan, Bisoprolol
Diabetes Mellitus
exenatide
Diabetes Mellitus Type 2
Ocrelizumab IV
Relapsing Multiple Sclerosis
bitopertin [RO4917838] level 1
Schizophrenia
MTX
Rheumatoid Arthritis
erlotinib (Tarceva)
Metastatic Colorectal Cancer
ECC
Stomach Cancer
capecitabine-irinotecan
Advanced Colorectal Cancer
Antipsychotics
Schizophrenia
Prednisone/Prednisolone
Metastatic Prostate Cancer
Recombinant Hepatitis B Virus Vaccine
Hepatitis B
rFVIIa
Hemophilia A
Taxotere
Breast Cancer
Fluoropyrimidine-based Chemotherapy
Colorectal Cancer
CDK4/6i
Breast Cancer
PDS Implant Pre-Filled with Ranibizumab
Diabetic Retinopathy
CMF
Breast Cancer
Stavudine
HIV Infections
Ganciclovir
Cytomegalovirus Retinitis
tocilizumab SC
Rheumatoid Arthritis
Lamivudine
HIV Infections
Erlotinib
Non-Squamous Non-Small Cell Lung Cancer
satralizumab
Neuromyelitis Optica Spectrum Disorder
MMF
Lupus Nephritis
interferon-a-2a
Lymphoma
Baloxavir Marboxil
Influenza
TRO19622
Amyotrophic Lateral Sclerosis
XELOX
Colorectal Cancer
Standard adjuvant chemotherapy
Breast Cancer
DMARD
Rheumatoid Arthritis
Lebrikizumab
Asthma
Faricimab
Wet Macular Degeneration
Mycophenolate Mofetil
Pemphigus Vulgaris (PV)
Pegylated-interferon Alfa-2a
Hepatitis C, Chronic
Standard chemotherapy
Breast Cancer
von Willebrand Factor (VWF) Concentrates
Von Willebrand Disease, Type 3
Oral Corticosteroids
Rheumatoid Arthritis
bevacizumab, erlotinib
Colorectal Cancer
Corticosteroids
Breast Cancer
Antihistamine
Multiple Sclerosis
epoetin
Anemia
Human Coagulation Factor VIII
Hemophilia A
Rituximab IV
Lymphoma, Large B-Cell, Diffuse
Risdiplam
Muscular Atrophy, Spinal
Ocrelizumab
Multiple Sclerosis
Pegylated Interferon (PEG-IFN) alfa-2a
Hepatitis D, Chronic
oseltamivir
Influenza, Human
Gemcitabine (Chemotherapy)
Ovarian Cancer
Second-Line Chemotherapy
Non-Squamous Non-Small Cell Lung Cancer
Nelfinavir mesylate
HIV Infections
Zalcitabine
HIV Infections
Efavirenz
HIV Infections
Cevostamab
Multiple Myeloma
Etrozulimab
Ulcerative Colitis
Vinflunine
Bladder Cancer
Neoral
Kidney Transplantation
Gantenerumab
Alzheimer's Disease
anti-IL-2R
Kidney Transplantation
Delavirdine mesylate
HIV Infections
adefovir dipivoxil
Hepatitis B, Chronic
fusidic acid
Non-Small Cell Lung Cancer
PDS Implant with Ranibizumab
Neovascular Age-Related Macular Degeneration
PDS Implant filled with Ranibizumab
Neovascular Age-Related Macular Degeneration
Chemotherapy (Induction Period)
Non-Hodgkin's Lymphoma
tenofovir
Hepatitis D, Chronic
RO0503821 (1x/2 Weeks)
Anemia
Atezolizumab
Triple-Negative Breast Cancer
Fluorouracil
HIV Infections
Olesoxime
Muscular Atrophy, Spinal
Riluzole
Amyotrophic Lateral Sclerosis
Astegolimab
Chronic Obstructive Pulmonary Disease (COPD)
bitopertin [RO4917838]
Schizophrenia
Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (anti-PD-L1) antibody
Squamous Non-Small Cell Lung Cancer
Mycophenolate mofetil (MMF)
Lupus Nephritis
5-Fluorouracil
Gastric Cancer
cyclosporine A (CsA)
Heart Transplantation
Platinum chemotherapy (cisplatin or carboplatin)
Non-Squamous Non-Small Cell Lung Cancer
Venetoclax
Chronic Lymphocytic Leukemia
RO7234292 (RG6042)
Huntington Disease
Epirubicin
Breast Cancer
Regorafenib
Colorectal Cancer
Acitretin
HIV Infections
Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone/Prednisolone (CHOP)
Diffuse Large B-Cell Lymphoma, Non-Hodgkin's Lymphoma
Optional Endocrine Therapy of Investigator's Choice
Metastatic Breast Cancer
Epoetin alfa
Anemia
5-Fluorouracil (5-FU)
Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma
Leucovorin calcium
Colorectal Cancer
Methotrexate
Rheumatoid Arthritis
Gemcitabine
Metastatic HER2-Positive Breast Cancer
Rituximab
Large B-Cell Lymphoma
Trastuzumab
Breast Cancer
Ribavirin
Hepatitis C, Chronic
erlotinib hydrochloride
Lung Cancer
Fulvestrant
Breast Cancer
Bevacizumab
Melanoma
R-pola-mini-CHP
DLBCL
PTC+Pertuzumab
Breast Cancer
Obinutuzumab
Large B-cell Lymphoma
Bendamustine
Follicular Lymphoma
Capecitabine
Biliary Tract Cancer
pegylated interferon alpha2a
Chronic Hepatitis C
tenecteplase
Myocardial Infarction
background treatment
Tubular Breast Cancer Stage II
PEGIntron plus ribavirin
Chronic Hepatitis C Virus Infection
Letrozole
Ovarian Neoplasm Epithelial
Trastuzumab in combination with pertuzumab
Haematological Malignancy
Pegylated Interferon/ribavirin
Chronic Hepatitis C
Peginterferon alpha-2a (Pegasys®)
HIV Infections
Folate
Rheumatoid Arthritis
Zilebesiran
High Risk Cardiovascular Disease
XELOXA-A
Colorectal Cancer
KLH
Multiple Sclerosis, Relapsing-Remitting
epoetin beta (NeoRecormon ®)
Kidney Failure
Invirase
Directly Observed Therapy
OCR
Multiple Sclerosis, Relapsing-Remitting
TT Vaccine
Multiple Sclerosis, Relapsing-Remitting
13-PCV Booster
Multiple Sclerosis, Relapsing-Remitting
sirolimus versus mycophenolate mofetil
Diabetes Mellitus, Type 1
Obinutuzumab administration
Membranous Nephropathy - PLA2R Induced
Peginterferon alfa-2a + Ribavirin
Chronic Hepatitis c
XELOXA
Colorectal Cancer
LHRH Agonist
Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer
emtricitabine/tenofovir
HIV Infections
Irinotecan (CPT-11)
Colorectal Cancer
Ribavirin "loading" dose given
Hepatitis C
TRUVADA (EMTRICITABINE + TENOFOVIR DF)
Hepatitis B
Solanezumab
Alzheimers Disease
modified FOLFOX6 + bevacizumab
Metastatic Colorectal Cancer
Bupropion
Breast Cancer
HIV antiretroviral therapy
HIV Infections
Pertuzumab and Trastuzumab FDC SC
HER2-positive Early Breast Cancer
Omeprazole
Breast Cancer
Folinic Acid, interferon-alpha
Rectal Cancer
anthracycline-based
Breast Cancer
RO7239361
Duchenne Muscular Dystrophy
MabThera
Humoral Rejection in Kidney Transplantation
RO7204239
Obesity
Vemurafenib in combination with cobimetinib
Haematological Malignancy
trastuzumab (Herceptin®)
Breast Cancer
Dabrafenib in combination with trametinib
Haematological Malignancy
Lenvatinib
Unresectable Hepatocellular Carcinoma
FOLFOXIRI + Bevacizumab
Metastatic Colorectal Cancer
Eculizumab
Paroxysmal Nocturnal Hemoglobinuria
5 FU
Neoplasms
Abemaciclib
Ovarian Cancer
Intravitreal Ranibizumab
Diabetic Macular Edema
Administration of Methylprednisolone + Prednisone + Mycophenolate mofetil
Lupus Nephritis
21Capecitabine + bevacizumab + oxaliplatin
Colorectal Cancer
Non-Biologic DMARDs
Rheumatoid Arthritis
rHuPH20
Non-Small Cell Lung Cancer
Tociluzumab
Relapsed or Refractory Follicular Lymphoma
Onartuzumab (MetMAb)
Gastric Cancer
Infliximab
Ulcerative Colitis
DL-alpha-tocopherol
Atherosclerosis
Paclitaxel, Bevacizumab, liposomal doxorubicin, Capecitabine
Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
Vemurafenib
Melanoma
Ipatasertib
Triple-Negative Breast Cancer
Ranibizumab
Diabetic Macular Edema
Emicizumab
Hemophilia A
erlotinib HCl
Non-Small Cell Lung Cancer
Azathioprine or Mycophenolate mofetil
Bullous Pemphigoid
Trastuzumab, Docetaxel
Breast Cancer
FOLFIRI + bevacizumab
Colorectal Cancer Metastatic
RO7269162
Alzheimer's Disease
Englumafusp alfa
Lymphoma, Non-Hodgkin
ZN-A-1041
Advanced Solid Tumors
RO6958688
Carcinoma, Non-Small-Cell Lung
Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (PD-L1) antibody
Breast Neoplasms
Leuporelin acetate
Breast Neoplasms
RO4929097
Non-Squamous Non-Small Cell Lung Cancer
PTC-Pz
Breast Cancer
Levofolinic acid
Colorectal Cancer
Dual Integrin Antagonist
Asthma
Dendritic cell vaccination
Malignant Pleural Mesothelioma
Atezolizumab Cohort 7
Solid Tumors
boceprevir
Hepatitis C, Chronic
PRM-151
Idiopathic Pulmonary Fibrosis
Mesna
Lymphoma
PolyPEPI1018
Colorectal Cancer Metastatic
Ro 24-7429
Sarcoma, Kaposi
Peluntamig (PT217)
Small Cell Lung Cancer (SCLC)
Metronidazole Actavis
Non-Squamous Non-Small Cell Lung Cancer
RO7490677
Primary Myelofibrosis
Oxaliplatin, Irinotecan, Bevacizumab, Docetaxel
Gastric Cancer
Saquinavir, lopinavir, ritonavir
HIV Infections
mDCF
Anal Cancer
Topical Corticosteroid Creams (Triamcinolone acetonide and Hydrocortisone)
Atopic Dermatitis
Doxorubicine
Untreated T-cell Angioimmunoblastic Lymphoma
Second line chemotherapy
Breast Cancer
Gemcitabine days 1, 8, 15 of a 28 day cycle
Pancreatic Cancer
RO5083945
Non-Squamous Non-Small Cell Lung Cancer
antibody induction
Kidney Transplantation
Standard antipsychotic therapy
Schizophrenia
RO5217790
Cervical Intraepithelial Neoplasia
RO6864018
Hepatitis B, Chronic
RO5093151
Hypertension, Glaucoma, Open-Angle
Fulvestrant or an Aromatase Inhibitor (Physician Choice)
Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer
RO7268489
Progressive Multiple Sclerosis
Saquinavir and Ritonavir
HIV Infections
Calciumfolinat
Gastric Cancer
R+CVP+IFN
Non-Hodgkin's Lymphoma
ERIVEDGE
Basal Cell Carcinoma
RO7046015
Parkinson's Disease
TRO40303
Acute Myocardial Infarctus
Trastuzumab Subcutaneous (SC)
Cancer of Unknown Primary Site
Peg-interferon alpha-2a, Ribavirin
Chronic Hepatitis C
RO4588161
Hepatitis C, Chronic
Aromatase Inhibitor
Breast Cancer
Diphenhydramine hydrochloride (HCl)
Lupus Nephritis
IMM-101
Colorectal Cancer
Peg-interféron alpha 2a + ribavirin
Hepatitis
Tocilizumab (Actemra®)
Acute Hypoxemic Respiratory Failure
Cytotoxic Combination
Behcet's Syndrome
Clindamycin in hydrocortisone lotion
Rash
Hormonal Therapy
Breast Cancer
Allogeneic islets of Langerhans transplant
Type 1 Diabetes
CAL-101
Chronic Lymphocytic Leucemia
Mericitabine
Hepatitis C
fotemustine
Glioblastoma Multiforme
Induction Chemotherapy
Breast Cancer
gemcitabine, oxaliplatin, capecitabine
Locally Advanced Pancreatic Cancer
Tobemstomig
Urothelial Cancer
Ribavirin (drug)
Hepatitis C, Chronic
Interferon gamma (drug)
Hepatitis C, Chronic
Obinutuzumab and Pixantrone
Lymphoma, Non-Hodgkin
Actos
Diabetes Mellitus Type 2
capecitabine (Xeloda)
Rectal Cancer
PHY906
Pancreatic Cancer
Erythropoietin Beta
Myelodysplastic Syndromes
DOX: Docetaxel, oxaliplatin, Capecitabine
Gastric Cancer
Docetaxel, Leucovorin, Fluorouracil, Cisplatin
Gastroesophageal Junction Adenocarcinoma
Trastuzumab, Docetaxel, Bevacizumab
Breast Cancer
Rituximab + CHOP chemotherapy
Primary Gastric Diffuse-Large B-Cell Lymphoma
LABA
Asthma
Forimtamig
Relapsed or Refractory Multiple Myeloma
PEGPH20
Pancreatic Adenocarcinoma
Induction- PF-06480605
Moderate to Severe Ulcerative Colitis
RO4602522
Alzheimer's Disease
RO5027838
Diabetes Mellitus Type 2
Zifibancimig
Macular Degeneration
GDC-4198
Breast Cancer
Doxycline
Non-Small Cell Lung Cancer
RG1662
Down Syndrome
obinutuzumab (RO5072759)
Non-Hodgkin's Lymphoma
Iberdomide
Multiple Myeloma
Enicepatide
Overweight or Obese
capecitabine (Xeloda®)
Breast Cancer
Standard platinum-based chemotherapy
Non-Small Cell Lung Cancer
bevacizumab (Avastin)
Liver Cancer
Emicizumab Injection
Hemophilia A, Acquired
Oxaliplatine
Metastatic Colorectal Cancer
Mosunetuzumab (SC)
Follicular Lymphoma
Vemurafenib plus Cobimetinib (combination)
Cancer
OSI-774
Pancreatic Cancer
RO4876904
Diabetes Mellitus Type 2
Crenezumab
Alzheimer Disease
Obinutuzumab/Intravenous
Follicular Lymphoma
Samuraciclib
Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer
Trastuzumab deruxtecan
HER2-positive Breast Cancer
ANA598
HCV Infection
Copegus
Hepatitis C, Chronic
N-acetylcysteine
Idiopathic Pulmonary Fibrosis
OpRegen
Age-Related Macular Degeneration
Olaparib+Bevacizumab to SCLC patients
Lung Cancer
Epidoxorubicin
Breast Cancer
RO7795081
Obesity or Overweight
Pravastatin
Dyslipidemia
Orlistat
Diabetes Mellitus
Tumor samples analysis
Triple Negative Breast Cancer
Experimental
Diabetic Neuropathy
Docetaxel, Cisplatin, 5-FU and Cetuximab
Nasopharyngeal Carcinoma
Investigator's choice of anti-cancer treatment (except immunotherapy)
Breast Cancer
Atezolizumab plus Tiraglolumab
Squamous Cell Carcinoma of the Anal Canal
Association atezolizumab + BDB001 + RT
Solid Tumor, Adult
Taxane (docetaxel or paclitaxel)
Breast Cancer
RO5190591
Hepatitis C, Chronic
Temozolomide (TMZ)
High Grade Glioma
5-FU, leucovorin, docetaxel, oxaliplatin (FLOT), trastuzumab
Adenocarcinoma of the Gastroesophageal Junction
RAR Gamma
Emphysema
Basmisanil
Schizophrenia
RG7774
Diabetic Retinopathy
Immunochemotherapy
Central Nervous System Lymphoma
Chronic- PF-06480605
Moderate to Severe Ulcerative Colitis
Rituximab and DexaBEAM
Relapsed Non-Hodgkin-Lymphoma
Chemotherapy (FOLFIRI regimen, FOLFOX regimen or LV5FU2 regimen)
Colorectal Cancer
BVZ+XELOX or BVZ+XELIRI or BVZ+FUIRI or BVZ+FUOX
Colorectal Cancer
Erlotinib + docetaxel
Non Small Cell Lung Cancer
Perjeta Injectable Product
Breast Neoplasms
Fosamprenavir
HIV Infections
Herceptin+XELOX
Metastatic or Recurrent Gastric Adenocarcinoma
Ocrelizumab Test Formulation
Multiple Sclerosis
Xeloda
Breast Cancer
Tocilizumab + Glucocorticoids (GCs)
Giant Cell Arteritis
C.E.R.A
Anemia
NXT007
Hemophilia A
Mosunetuzumab (IV)
B-cell Non-Hodgkin Lymphoma
beta-lactam
Soft Tissue Infections
Atezolizumab in
Extensive-stage Small Cell Lung Cancer
Rituxumab
B-cell Non-Hodgkin Lymphoma
SOC Agent
Glioblastoma
Blood sample collection
Squamous Cell Carcinoma of the Head and Neck
Didanosine
HIV Infections
Folinic Acid
Rectal Cancer
Polatuzumab vedotin (Liquid)
Lymphoma
Autogene Cevumeran
Muscle-invasive Urothelial Carcinoma
Carboplatin/Cisplatin
Nasopharyngeal Cancer
Epothilone D
Breast Cancer
Pertuzumab and Trastuzumab Fixed-Dose Combination for Subcutaneous Administration (PH FDC SC)
HER2-Positive Early Breast Cancer
Interferon alfa-2a
Renal Cell Cancer
Interleukin 2
HIV Infections
Folic Acid
Rheumatoid Arthritis
Endocrine therapy
HER2-positive Breast Cancer
GK Activator (2)
Diabetes Mellitus Type 2
Atezolizumab & Bevacizumab
Mesothelioma, Malignant
Docetaxel, Capecitabine, Cisplatin, Bevacizumab
Advanced Gastric Cancer
Axitinib
Renal Cell Carcinoma
Diprosone
Metastatic Colorectal Cancer
Capecitabine+Irinotecan+Bevacizumab
Metastatic Colorectal Cancer
Atezolizumab (MPDL3280A)
Lymphoma, Follicular
lenalidomide, bendamustine, rituximab
Mantle Cell Lymphoma
R-EPOCH and cART
Lymphoma, AIDS Related
TCS Cream
Atopic Dermatitis
Pegylated interferon alfa-2a plus nucleos(t)ide(s)
Chronic Hepatitis B
DPP-IV Inhibitor
Diabetes Mellitus Type 2
vismodegib
Basal Cell Carcinoma
SPK-8011QQ
Hemophilia A
PEGASYS [peginterferon alfa-2a]
Hepatitis B, Chronic
MSTT1041A
Asthma
Glofitamab + Obinutuzumab
Richter Syndrome
RO7017773
Autism Spectrum Disorder (ASD)
RO 205-2349
Diabetes
Danoprevir
Hepatitis C, Chronic
Tenofovir-Emtricitabine
Leukoencephalopathy, Progressive Multifocal
RO5024048
Hepatitis C, Chronic
Olesoxime (TRO19622)
Chemotherapy-Induced Peripheral Neuropathy
RO7247669
Melanoma
Tiragolumab and Atezolizumab IV FDC
PD-L1-selected Solid Tumors
RG7314
Autism Spectrum Disorder
Tociliuzumab
COVID-19 Pneumonia
Gemcitabine+erlotinib
Metastatic Pancreatic Cancer
Pertuzumab + trastuzumab
Elderly Metastatic Breast Cancer Population
Dinutuximab Beta
Neuroblastoma
TCH
Breast Cancer
RO7126209
Alzheimers Disease
Tominersen
Huntington Disease
FOLFIRI + cetuximab
Colorectal Cancer Metastatic
Obinutuzumab Injection
Stage II Grade 1 Follicular Lymphoma
PEG-IFN alfa-2a, Tenofovir
Hepatitis D
FEC
Breast Cancer
RO6889450
Schizophrenia, Schizoaffective Disorder
RO4998452
Diabetes Mellitus Type 2
Atezolizumab and Radiotherapy
Penile Cancer
fluorouracil (5FU)
Colorectal Cancer
Bendamustine, Rituximab, Lenalidomide
Chronic Lymphocytic Leukemia
MPDL3280A
Non-small Cell Lung Cancer
Peg-interferon alpha 2a (drug)
Hepatitis C, Chronic
AT-527
COVID-19
Atezolizumab Injection
Bladder Cancer
RO5190591 (Danoprevir)
Hepatitis C, Chronic
SGN-LIV1A
Metastatic Breast Cancer
FOLFOX induction regimen
Colorectal Cancer
Carbo/cyclo
Breast Cancer
rituximab (anti-CD20)
Sjogren's Syndrome
First line chemotherapy
Mantle Cell Lymphoma
bevacizumab and trabectedin
Ovarian Epithelial Cancer Recurrent
GA101
Chronic Lymphocytic Leucemia
RO4905417
Coronary Heart Disease, Graft Occlusion, Vascular
SSRI
Obsessive-Compulsive Disorder
P38 Inhibitor (4)
Rheumatoid Arthritis
Ceftriaxone
Pneumonia, Bacterial
danoprevir + ritonavir
Hepatitis C, Chronic
Ribavirine
Chronic Hepatitis C
Mycophenolate Mofetil/Mycophenolic Acid
Lupus Nephritis
RO5313534
Alzheimer's Disease
L-Leucovorin
Metastatic Colorectal Cancer
Balovaptan
Stress Disorders, Post-Traumatic
Carboplatin-based chemotherapy
Non-Small Cell Lung Cancer
Pegylated Interferon (Peginterferon) Alfa-2a
Hepatitis B, Chronic
Bendamustine and subcutaneous rituximab
Aggressive Lymphoma
Lomvastomig
Advanced or Metastatic Esophageal Squamous Cell Carcinoma
YL201
Thoracic Neoplasms, Lung Diseases, Small Cell Lung Carcinoma
Standard taxane therapy
Breast Cancer
RG3421
Psoriasis
2-CdA
Lymphoma of Mucosa-Associated Lymphoid Tissue
GC33
Carcinoma, Hepatocellular
Nucleos(t)ide (NUC)
Hepatitis B, Chronic
Mosunetuzumab is a bispecific monoclonal antibody targeting CD20 on B cells and CD3 on T cells, redirecting T cells to eliminate malignant B cells
Follicular Lymphoma
Ibrutinib/Bortezomib/Rituximab
Waldenstrom Macroglobulinemia
pralsetinib (BLU-667)
RET-altered Non Small Cell Lung Cancer
Trastuzumab+Docetaxel+NPLD
Breast Cancer
setrobuvir
Hepatitis C, Chronic
Polyenylphosphatidylcholine (PPC)
Hepatitis C
Topical clindamycin, triamcinolone acetonide soln
Rash
eloxatin
Colorectal Cancer
Trastuzumab+Docetaxel+NPLD+Bevacizumab
Breast Cancer
Myocet
Breast Cancer
docetaxel, capecitabine
Metastatic Breast Cancer
Bevacizumab + Capecitabine + Radiotherapy
Rectal Cancer
preoperative induction chemotherapy in combination with bevacizumab followed by combined radiochemotherapy with capecitabine
Rectal Cancer
RO4917523
Fragile X Syndrome
Trastuzumab and Pertuzumab (FDC SC) and T-DM1
Early Breast Cancer
Erlotinib, escalating dose
Pancreatic Cancer
Inhaled corticposteroids (ICS)
Asthma
Pertuzumab, trastuzumab
Esophageal Carcinoma
RO4995819
Major Depressive Disorder
Optimized Background ARVs
HIV Infections
Abacavir sulfate
HIV Infections
Tarceva (OSI-774)
Colorectal Cancer
RO5459072
Sjogren's Syndrome
Alogabat
Angelman Syndrome
89Zr-Df-IAB22M2C
Non-Hodgkins Lymphoma
Atezolizumab and Bevacizumab
Cancer
RO5185426
Malignant Melanoma
Mosunetuzumab Intravenous (IV)
Diffuse Large B-cell Lymphoma
ADG126
Advanced Liver Cancers
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Pertuzumab IV | Phase 3 | Early Breast Cancer | - | - |
Afimkibart | Phase 3 | Crohns Disease | - | - |
tocilizumab [RoActemra/Actemra] | Phase 3 | Rheumatoid Arthritis | - | - |
Vitamin Supplements | Phase 3 | Hematological Malignancies | - | - |
AT1 blocker candesartan | Phase 3 | Breast Cancer | - | - |
Methoxy polyethylene glycol-epoetin beta (C.E.R.A.) | Phase 3 | Anemia | - | - |
Mircera | Phase 3 | Anemia | - | - |
Saquinavir | Phase 3 | HIV Infections | - | - |
rituximab [MabThera/Rituxan] | Phase 3 | Rheumatoid Arthritis | - | - |
liposomal doxorubicin | Phase 3 | Ovarian Cancer | - | - |
Omalizumab | Phase 3 | Nasal Polyps | - | - |
csDMARDs | Phase 3 | Rheumatoid Arthritis | - | - |
tocilizumab | Phase 3 | Rheumatoid Arthritis | - | - |
ritonavir | Phase 3 | HIV Infections | - | - |
Etrolizumab | Phase 3 | Crohn Disease | - | - |
Epoetin beta | Phase 3 | Anemia | - | - |
rituximab (Mabthera®) | Phase 3 | Warm Autoimmune Hemolytic Anemia | - | - |
Lurbinectedin | Phase 3 | Small-Cell Lung Cancer | - | - |
taspoglutide | Phase 3 | Diabetes Mellitus Type 2 | - | - |
Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody | Phase 3 | Triple-Negative Breast Cancer | - | - |
Ibandronate | Phase 3 | Post-Menopausal Osteoporosis | - | - |
Entrectinib | Phase 3 | Solid Tumors | - | - |
Methoxy Polyethylene Glycol-Epoetin Beta | Phase 3 | Anemia | - | - |
mycophenolate mofetil (CellCept) | Phase 3 | Myasthenia Gravis, Generalized | - | - |
Onartuzumab | Phase 3 | Glioblastoma | - | - |
Pirfenidone | Phase 3 | Lung Diseases, Interstitial | - | - |
Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody | Phase 3 | Carcinoma, Non-Squamous Non-Small Cell Lung | - | - |
Fixed Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Use (PH FDC SC) | Phase 3 | Early Breast Cancer | - | - |
Trastuzumab IV | Phase 3 | HER2-positive Early Breast Cancer | - | - |
Other Combination Anti-Cancer Therapies | Phase 3 | Solid Tumors | - | - |
Valganciclovir | Phase 3 | Cytomegalovirus Infections | - | - |
Filgrastim | Phase 3 | Triple-negative Breast Cancer | - | - |
Herceptin | Phase 3 | Breast Cancer | - | - |
Trastuzumab Emtansine | Phase 3 | Breast Cancer | - | - |
Fenebrutinib | Phase 3 | Relapsing Multiple Sclerosis | - | - |
Glofitamab | Phase 3 | Diffuse Large B-cell Lymphoma | - | - |
Alectinib | Phase 3 | Non-Small Cell Lung Cancer | - | - |
Peginterferon alfa-2a | Phase 3 | Carcinoma, Hepatocellular | - | - |
Cladribine | Phase 3 | Lymphocytic Leukemia, Chronic | - | - |
ibandronate [Bonviva/Boniva] | Phase 3 | Post-Menopausal Osteopenia | - | - |
Trontinemab | Phase 3 | Alzheimers Disease | - | - |
aleglitazar | Phase 3 | Diabetes Mellitus Type 2 | - | - |
Alectnib | Phase 3 | Carcinoma, Non-Small-Cell Lung | - | - |
Chemotherapy | Phase 3 | Non-Small Cell Lung Cancer | - | - |
Inavolisib | Phase 3 | Breast Cancer | - | - |
Leucovorin (LV) | Phase 3 | Colorectal Cancer | - | - |
CHOP | Phase 3 | Lymphoma, Large B-Cell, Diffuse | - | - |
RO4917838 | Phase 3 | Schizophrenia | - | - |
Baseline Treatment | Phase 3 | Neuromyelitis Optica (NMO) | - | - |
Acetaminophen/Paracetamol | Phase 3 | Systemic Lupus Erythematosus | - | - |
Phesgo | Phase 3 | Locally Advanced or Metastatic Breast Cancer | - | - |
Fludarabine Phosphate | Phase 3 | Chronic Lymphocytic Leukemia | - | - |
Ribociclib | Phase 3 | Breast Cancer | - | - |
methoxy polyethylene glycol-epoetin beta [C.E.R.A.] | Phase 3 | Anemia | - | - |
Ortho-Novum® 1/35 | Phase 3 | Rheumatoid Arthritis | - | - |
PEGASYS | Phase 3 | Hepatitis C, Chronic | - | - |
RO7771950 | Phase 3 | HER2-positive Breast Cancer | - | - |
aleglitazar+metformin | Phase 3 | Diabetes Mellitus Type 2 | - | - |
dalcetrapib | Phase 3 | Coronary Heart Disease | - | - |
Tiragolumab and Atezolizumab | Phase 3 | Cancer | - | - |
Cobimetinib | Phase 3 | Melanoma | - | - |
DMARDs | Phase 3 | Rheumatoid Arthritis | - | - |
MabThera/Rituxan | Phase 3 | Rheumatoid Arthritis | - | - |
RO7234292 | Phase 3 | Huntingtons Disease | - | - |
Crovalimab | Phase 3 | Atypical Hemolytic Uremic Syndrome | - | - |
Entecavir | Phase 3 | Pediatric Immuno-Tolerant Chronic Hepatitis B | - | - |
Mosunetuzumab | Phase 3 | Non-Hodgkin Lymphoma | - | - |
Prasinezumab | Phase 3 | Parkinsons Disease | - | - |
methoxy polyethylene glycol-epoetin beta (Mircera) | Phase 3 | Anemia | - | - |
Dalcetrapib (RO4607381) | Phase 3 | Coronary Heart Disease | - | - |
FEC Chemotherapy | Phase 3 | Breast Cancer | - | - |
Darbepoetin alfa | Phase 3 | Anemia | - | - |
Interferon beta-1a | Phase 3 | Relapsing Multiple Sclerosis | - | - |
Ibandronate, Capecitabine | Phase 3 | Breast Cancer | - | - |
Bevacizumab + Pemetrexed + Carboplatin | Phase 3 | Non-squamous Non-small Cell Lung Cancer | - | - |
Bevacizumab + Pemetrexed | Phase 3 | Non-squamous Non-small Cell Lung Cancer | - | - |
RO0503821 (1x/4 Weeks) | Phase 3 | Anemia | - | - |
Evidence-based medical care for Acute Coronary Syndrome | Phase 3 | Coronary Heart Disease | - | - |
Tiragolumab | Phase 3 | Small Cell Lung Cancer | - | - |
methoxy polyethylene glycol-epoetin beta [RO0503821, Mircera] | Phase 3 | Anemia | - | - |
methylprednisolone | Phase 3 | Rheumatoid Arthritis | - | - |
Vamikibart | Phase 3 | Diabetic Macular Edema | - | - |
Factor VIII (FVIII) | Phase 3 | Hemophilia A | - | - |
Pralsetinib | Phase 3 | RET-fusion Non Small Cell Lung Cancer | - | - |
Anti-VEGF Therapy | Phase 3 | Neovascular Age-related Macular Degeneration | - | - |
epoetin alfa or beta | Phase 3 | Anemia | - | - |
5-Fluorouracil, Folic acid, Capecitabine; Bevacizumab | Phase 3 | Colorectal Neoplasms | - | - |
Zidovudine | Phase 3 | HIV Infections | - | - |
Remdesivir | Phase 3 | COVID-19 Pneumonia | - | - |
Polatuzumab Vedotin | Phase 3 | Non-Hodgkin's Lymphoma | - | - |
r-HuEPO | Phase 3 | Anemia | - | - |
Fingolimod | Phase 3 | Relapsing-Remitting Multiple Sclerosis | - | - |
Teriflunomide | Phase 3 | Relapsing Multiple Sclerosis | - | - |
Sefaxersen (RO7434656) | Phase 3 | Primary IgA Nephropathy | - | - |
Standard DMARDs (Disease Modifying Anti Rheumatic Drugs) | Phase 3 | Rheumatoid Arthritis | - | - |
Tocilizumab (TCZ) | Phase 3 | Rheumatoid Arthritis | - | - |
Valganciclovir CMV Prophylaxis | Phase 3 | Cytomegalovirus Infections | - | - |
Herceptin IV | Phase 3 | Breast Cancer | - | - |
Neo-adjuvant chemotherapy | Phase 3 | Breast Cancer | - | - |
Enfuvirtide | Phase 3 | HIV Infections | - | - |
Pertuzumab | Phase 3 | Breast Cancer | - | - |
Taxane-based chemotherapy | Phase 3 | Breast Cancer | - | - |
Cyclosporine | Phase 3 | Renal Transplantation | - | - |
23-PPV | Phase 3 | Multiple Sclerosis, Relapsing-Remitting | - | - |
FAP IL2V | Phase 3 | Cancer | - | - |
Alimta or Taxotere | Phase 3 | Non-Small Cell Lung Cancer | - | - |
Oxaliplatin | Phase 3 | Colorectal Cancer | - | - |
Non-steroidal anti-inflammatory drugs (NSAIDs) | Phase 3 | Juvenile Idiopathic Arthritis | - | - |
chlorambucil | Phase 3 | Lymphocytic Leukemia, Chronic | - | - |
5-Fluoruracil | Phase 3 | Gastric Cancer | - | - |
Giredestrant | Phase 3 | Endometrial Cancer | - | - |
Oseltamivir IV | Phase 3 | Influenza | - | - |
Interferon alfa 2a | Phase 3 | Renal Cell Cancer | - | - |
Disease-modifying anti-rheumatic drugs | Phase 3 | Rheumatoid Arthritis | - | - |
Becavizumab | Phase 3 | Hepatocellular Carcinoma | - | - |
Azathioprine | Phase 3 | Rheumatoid Arthritis | - | - |
Crizotinib | Phase 3 | Neoplasms | - | - |
Bitopertin | Phase 3 | Beta-Thalassemia | - | - |
Pegylated Interferon Alfa-2a | Phase 3 | Chronic Myelogenous Leukemia | - | - |
Divarasib | Phase 3 | Non-Small Cell Lung Cancer | - | - |
Rituximab SC | Phase 3 | Non-Hodgkin's Lymphoma | - | - |
Optimized background antiretroviral regimen (OB) | Phase 3 | HIV Infections | - | - |
Permitted DMARDs | Phase 3 | Rheumatoid Arthritis | - | - |
Telmisartan, Bisoprolol | Phase 3 | Diabetes Mellitus | - | - |
exenatide | Phase 3 | Diabetes Mellitus Type 2 | - | - |
Ocrelizumab IV | Phase 3 | Relapsing Multiple Sclerosis | - | - |
bitopertin [RO4917838] level 1 | Phase 3 | Schizophrenia | - | - |
MTX | Phase 3 | Rheumatoid Arthritis | - | - |
erlotinib (Tarceva) | Phase 3 | Metastatic Colorectal Cancer | - | - |
ECC | Phase 3 | Stomach Cancer | - | - |
capecitabine-irinotecan | Phase 3 | Advanced Colorectal Cancer | - | - |
Antipsychotics | Phase 3 | Schizophrenia | - | - |
Prednisone/Prednisolone | Phase 3 | Metastatic Prostate Cancer | - | - |
Recombinant Hepatitis B Virus Vaccine | Phase 3 | Hepatitis B | - | - |
rFVIIa | Phase 3 | Hemophilia A | - | - |
Taxotere | Phase 3 | Breast Cancer | - | - |
Fluoropyrimidine-based Chemotherapy | Phase 3 | Colorectal Cancer | - | - |
CDK4/6i | Phase 3 | Breast Cancer | - | - |
PDS Implant Pre-Filled with Ranibizumab | Phase 3 | Diabetic Retinopathy | - | - |
CMF | Phase 3 | Breast Cancer | - | - |
Stavudine | Phase 3 | HIV Infections | - | - |
Ganciclovir | Phase 3 | Cytomegalovirus Retinitis | - | - |
tocilizumab SC | Phase 3 | Rheumatoid Arthritis | - | - |
Lamivudine | Phase 3 | HIV Infections | - | - |
Erlotinib | Phase 3 | Non-Squamous Non-Small Cell Lung Cancer | - | - |
satralizumab | Phase 3 | Neuromyelitis Optica Spectrum Disorder | - | - |
MMF | Phase 3 | Lupus Nephritis | - | - |
interferon-a-2a | Phase 3 | Lymphoma | - | - |
Baloxavir Marboxil | Phase 3 | Influenza | - | - |
TRO19622 | Phase 3 | Amyotrophic Lateral Sclerosis | - | - |
XELOX | Phase 3 | Colorectal Cancer | - | - |
Standard adjuvant chemotherapy | Phase 3 | Breast Cancer | - | - |
DMARD | Phase 3 | Rheumatoid Arthritis | - | - |
Lebrikizumab | Phase 3 | Asthma | - | - |
Faricimab | Phase 3 | Wet Macular Degeneration | - | - |
Mycophenolate Mofetil | Phase 3 | Pemphigus Vulgaris (PV) | - | - |
Pegylated-interferon Alfa-2a | Phase 3 | Hepatitis C, Chronic | - | - |
Standard chemotherapy | Phase 3 | Breast Cancer | - | - |
von Willebrand Factor (VWF) Concentrates | Phase 3 | Von Willebrand Disease, Type 3 | - | - |
Oral Corticosteroids | Phase 3 | Rheumatoid Arthritis | - | - |
bevacizumab, erlotinib | Phase 3 | Colorectal Cancer | - | - |
Corticosteroids | Phase 3 | Breast Cancer | - | - |
Antihistamine | Phase 3 | Multiple Sclerosis | - | - |
epoetin | Phase 3 | Anemia | - | - |
Human Coagulation Factor VIII | Phase 3 | Hemophilia A | - | - |
Rituximab IV | Phase 3 | Lymphoma, Large B-Cell, Diffuse | - | - |
Risdiplam | Phase 3 | Muscular Atrophy, Spinal | - | - |
Ocrelizumab | Phase 3 | Multiple Sclerosis | - | - |
Pegylated Interferon (PEG-IFN) alfa-2a | Phase 3 | Hepatitis D, Chronic | - | - |
oseltamivir | Phase 3 | Influenza, Human | - | - |
Gemcitabine (Chemotherapy) | Phase 3 | Ovarian Cancer | - | - |
Second-Line Chemotherapy | Phase 3 | Non-Squamous Non-Small Cell Lung Cancer | - | - |
Nelfinavir mesylate | Phase 3 | HIV Infections | - | - |
Zalcitabine | Phase 3 | HIV Infections | - | - |
Efavirenz | Phase 3 | HIV Infections | - | - |
Cevostamab | Phase 3 | Multiple Myeloma | - | - |
Etrozulimab | Phase 3 | Ulcerative Colitis | - | - |
Vinflunine | Phase 3 | Bladder Cancer | - | - |
Neoral | Phase 3 | Kidney Transplantation | - | - |
Gantenerumab | Phase 3 | Alzheimer's Disease | - | - |
anti-IL-2R | Phase 3 | Kidney Transplantation | - | - |
Delavirdine mesylate | Phase 3 | HIV Infections | - | - |
adefovir dipivoxil | Phase 3 | Hepatitis B, Chronic | - | - |
fusidic acid | Phase 3 | Non-Small Cell Lung Cancer | - | - |
PDS Implant with Ranibizumab | Phase 3 | Neovascular Age-Related Macular Degeneration | - | - |
PDS Implant filled with Ranibizumab | Phase 3 | Neovascular Age-Related Macular Degeneration | - | - |
Chemotherapy (Induction Period) | Phase 3 | Non-Hodgkin's Lymphoma | - | - |
tenofovir | Phase 3 | Hepatitis D, Chronic | - | - |
RO0503821 (1x/2 Weeks) | Phase 3 | Anemia | - | - |
Atezolizumab | Phase 3 | Triple-Negative Breast Cancer | - | - |
Fluorouracil | Phase 3 | HIV Infections | - | - |
Olesoxime | Phase 3 | Muscular Atrophy, Spinal | - | - |
Riluzole | Phase 3 | Amyotrophic Lateral Sclerosis | - | - |
Astegolimab | Phase 3 | Chronic Obstructive Pulmonary Disease (COPD) | - | - |
bitopertin [RO4917838] | Phase 3 | Schizophrenia | - | - |
Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (anti-PD-L1) antibody | Phase 3 | Squamous Non-Small Cell Lung Cancer | - | - |
Mycophenolate mofetil (MMF) | Phase 3 | Lupus Nephritis | - | - |
5-Fluorouracil | Phase 3 | Gastric Cancer | - | - |
cyclosporine A (CsA) | Phase 3 | Heart Transplantation | - | - |
Platinum chemotherapy (cisplatin or carboplatin) | Phase 3 | Non-Squamous Non-Small Cell Lung Cancer | - | - |
Venetoclax | Phase 3 | Chronic Lymphocytic Leukemia | - | - |
RO7234292 (RG6042) | Phase 3 | Huntington Disease | - | - |
Epirubicin | Phase 3 | Breast Cancer | - | - |
Regorafenib | Phase 3 | Colorectal Cancer | - | - |
Acitretin | Phase 3 | HIV Infections | - | - |
Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone/Prednisolone (CHOP) | Phase 3 | Diffuse Large B-Cell Lymphoma, Non-Hodgkin's Lymphoma | - | - |
Optional Endocrine Therapy of Investigator's Choice | Phase 3 | Metastatic Breast Cancer | - | - |
Epoetin alfa | Phase 3 | Anemia | - | - |
5-Fluorouracil (5-FU) | Phase 3 | Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma | - | - |
Leucovorin calcium | Phase 3 | Colorectal Cancer | - | - |
Methotrexate | Phase 3 | Rheumatoid Arthritis | - | - |
Gemcitabine | Phase 3 | Metastatic HER2-Positive Breast Cancer | - | - |
Rituximab | Phase 3 | Large B-Cell Lymphoma | - | - |
Trastuzumab | Phase 3 | Breast Cancer | - | - |
Ribavirin | Phase 3 | Hepatitis C, Chronic | - | - |
erlotinib hydrochloride | Phase 3 | Lung Cancer | - | - |
Fulvestrant | Phase 3 | Breast Cancer | - | - |
Bevacizumab | Phase 3 | Melanoma | - | - |
R-pola-mini-CHP | Phase 3 | DLBCL | - | - |
PTC+Pertuzumab | Phase 3 | Breast Cancer | - | - |
Obinutuzumab | Phase 3 | Large B-cell Lymphoma | - | - |
Bendamustine | Phase 3 | Follicular Lymphoma | - | - |
Capecitabine | Phase 3 | Biliary Tract Cancer | - | - |
pegylated interferon alpha2a | Phase 3 | Chronic Hepatitis C | - | - |
tenecteplase | Phase 3 | Myocardial Infarction | - | - |
background treatment | Phase 3 | Tubular Breast Cancer Stage II | - | - |
PEGIntron plus ribavirin | Phase 3 | Chronic Hepatitis C Virus Infection | - | - |
Letrozole | Phase 3 | Ovarian Neoplasm Epithelial | - | - |
Trastuzumab in combination with pertuzumab | Phase 3 | Haematological Malignancy | - | - |
Pegylated Interferon/ribavirin | Phase 3 | Chronic Hepatitis C | - | - |
Peginterferon alpha-2a (Pegasys®) | Phase 3 | HIV Infections | - | - |
Folate | Phase 3 | Rheumatoid Arthritis | - | - |
Zilebesiran | Phase 3 | High Risk Cardiovascular Disease | - | - |
XELOXA-A | Phase 3 | Colorectal Cancer | - | - |
KLH | Phase 3 | Multiple Sclerosis, Relapsing-Remitting | - | - |
epoetin beta (NeoRecormon ®) | Phase 3 | Kidney Failure | - | - |
Invirase | Phase 3 | Directly Observed Therapy | - | - |
OCR | Phase 3 | Multiple Sclerosis, Relapsing-Remitting | - | - |
TT Vaccine | Phase 3 | Multiple Sclerosis, Relapsing-Remitting | - | - |
13-PCV Booster | Phase 3 | Multiple Sclerosis, Relapsing-Remitting | - | - |
sirolimus versus mycophenolate mofetil | Phase 3 | Diabetes Mellitus, Type 1 | - | - |
Obinutuzumab administration | Phase 3 | Membranous Nephropathy - PLA2R Induced | - | - |
Peginterferon alfa-2a + Ribavirin | Phase 3 | Chronic Hepatitis c | - | - |
XELOXA | Phase 3 | Colorectal Cancer | - | - |
LHRH Agonist | Phase 3 | Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer | - | - |
emtricitabine/tenofovir | Phase 3 | HIV Infections | - | - |
Irinotecan (CPT-11) | Phase 3 | Colorectal Cancer | - | - |
Ribavirin "loading" dose given | Phase 3 | Hepatitis C | - | - |
TRUVADA (EMTRICITABINE + TENOFOVIR DF) | Phase 3 | Hepatitis B | - | - |
Solanezumab | Phase 3 | Alzheimers Disease | - | - |
modified FOLFOX6 + bevacizumab | Phase 3 | Metastatic Colorectal Cancer | - | - |
Bupropion | Phase 3 | Breast Cancer | - | - |
HIV antiretroviral therapy | Phase 3 | HIV Infections | - | - |
Pertuzumab and Trastuzumab FDC SC | Phase 3 | HER2-positive Early Breast Cancer | - | - |
Omeprazole | Phase 3 | Breast Cancer | - | - |
Folinic Acid, interferon-alpha | Phase 3 | Rectal Cancer | - | - |
anthracycline-based | Phase 3 | Breast Cancer | - | - |
RO7239361 | Phase 3 | Duchenne Muscular Dystrophy | - | - |
MabThera | Phase 3 | Humoral Rejection in Kidney Transplantation | - | - |
RO7204239 | Phase 3 | Obesity | - | - |
Vemurafenib in combination with cobimetinib | Phase 3 | Haematological Malignancy | - | - |
trastuzumab (Herceptin®) | Phase 3 | Breast Cancer | - | - |
Dabrafenib in combination with trametinib | Phase 3 | Haematological Malignancy | - | - |
Lenvatinib | Phase 3 | Unresectable Hepatocellular Carcinoma | - | - |
FOLFOXIRI + Bevacizumab | Phase 3 | Metastatic Colorectal Cancer | - | - |
Eculizumab | Phase 3 | Paroxysmal Nocturnal Hemoglobinuria | - | - |
5 FU | Phase 3 | Neoplasms | - | - |
Abemaciclib | Phase 3 | Ovarian Cancer | - | - |
Intravitreal Ranibizumab | Phase 3 | Diabetic Macular Edema | - | - |
Administration of Methylprednisolone + Prednisone + Mycophenolate mofetil | Phase 3 | Lupus Nephritis | - | - |
21Capecitabine + bevacizumab + oxaliplatin | Phase 3 | Colorectal Cancer | - | - |
Non-Biologic DMARDs | Phase 3 | Rheumatoid Arthritis | - | - |
rHuPH20 | Phase 3 | Non-Small Cell Lung Cancer | - | - |
Tociluzumab | Phase 3 | Relapsed or Refractory Follicular Lymphoma | - | - |
Onartuzumab (MetMAb) | Phase 3 | Gastric Cancer | - | - |
Infliximab | Phase 3 | Ulcerative Colitis | - | - |
DL-alpha-tocopherol | Phase 3 | Atherosclerosis | - | - |
Paclitaxel, Bevacizumab, liposomal doxorubicin, Capecitabine | Phase 3 | Human Epidermal Growth Factor 2 Negative Carcinoma of Breast | - | - |
Vemurafenib | Phase 3 | Melanoma | - | - |
Ipatasertib | Phase 3 | Triple-Negative Breast Cancer | - | - |
Ranibizumab | Phase 3 | Diabetic Macular Edema | - | - |
Emicizumab | Phase 3 | Hemophilia A | - | - |
erlotinib HCl | Phase 2 | Non-Small Cell Lung Cancer | - | - |
Azathioprine or Mycophenolate mofetil | Phase 2 | Bullous Pemphigoid | - | - |
Trastuzumab, Docetaxel | Phase 2 | Breast Cancer | - | - |
FOLFIRI + bevacizumab | Phase 2 | Colorectal Cancer Metastatic | - | - |
RO7269162 | Phase 2 | Alzheimer's Disease | - | - |
Englumafusp alfa | Phase 2 | Lymphoma, Non-Hodgkin | - | - |
ZN-A-1041 | Phase 2 | Advanced Solid Tumors | - | - |
RO6958688 | Phase 2 | Carcinoma, Non-Small-Cell Lung | - | - |
Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (PD-L1) antibody | Phase 2 | Breast Neoplasms | - | - |
Leuporelin acetate | Phase 2 | Breast Neoplasms | - | - |
RO4929097 | Phase 2 | Non-Squamous Non-Small Cell Lung Cancer | - | - |
PTC-Pz | Phase 2 | Breast Cancer | - | - |
Levofolinic acid | Phase 2 | Colorectal Cancer | - | - |
Dual Integrin Antagonist | Phase 2 | Asthma | - | - |
Dendritic cell vaccination | Phase 2 | Malignant Pleural Mesothelioma | - | - |
Atezolizumab Cohort 7 | Phase 2 | Solid Tumors | - | - |
boceprevir | Phase 2 | Hepatitis C, Chronic | - | - |
PRM-151 | Phase 2 | Idiopathic Pulmonary Fibrosis | - | - |
Mesna | Phase 2 | Lymphoma | - | - |
PolyPEPI1018 | Phase 2 | Colorectal Cancer Metastatic | - | - |
Ro 24-7429 | Phase 2 | Sarcoma, Kaposi | - | - |
Peluntamig (PT217) | Phase 2 | Small Cell Lung Cancer (SCLC) | - | - |
Metronidazole Actavis | Phase 2 | Non-Squamous Non-Small Cell Lung Cancer | - | - |
RO7490677 | Phase 2 | Primary Myelofibrosis | - | - |
Oxaliplatin, Irinotecan, Bevacizumab, Docetaxel | Phase 2 | Gastric Cancer | - | - |
Saquinavir, lopinavir, ritonavir | Phase 2 | HIV Infections | - | - |
mDCF | Phase 2 | Anal Cancer | - | - |
Topical Corticosteroid Creams (Triamcinolone acetonide and Hydrocortisone) | Phase 2 | Atopic Dermatitis | - | - |
Doxorubicine | Phase 2 | Untreated T-cell Angioimmunoblastic Lymphoma | - | - |
Second line chemotherapy | Phase 2 | Breast Cancer | - | - |
Gemcitabine days 1, 8, 15 of a 28 day cycle | Phase 2 | Pancreatic Cancer | - | - |
RO5083945 | Phase 2 | Non-Squamous Non-Small Cell Lung Cancer | - | - |
antibody induction | Phase 2 | Kidney Transplantation | - | - |
Standard antipsychotic therapy | Phase 2 | Schizophrenia | - | - |
RO5217790 | Phase 2 | Cervical Intraepithelial Neoplasia | - | - |
RO6864018 | Phase 2 | Hepatitis B, Chronic | - | - |
RO5093151 | Phase 2 | Hypertension, Glaucoma, Open-Angle | - | - |
Fulvestrant or an Aromatase Inhibitor (Physician Choice) | Phase 2 | Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer | - | - |
RO7268489 | Phase 2 | Progressive Multiple Sclerosis | - | - |
Saquinavir and Ritonavir | Phase 2 | HIV Infections | - | - |
Calciumfolinat | Phase 2 | Gastric Cancer | - | - |
R+CVP+IFN | Phase 2 | Non-Hodgkin's Lymphoma | - | - |
ERIVEDGE | Phase 2 | Basal Cell Carcinoma | - | - |
RO7046015 | Phase 2 | Parkinson's Disease | - | - |
TRO40303 | Phase 2 | Acute Myocardial Infarctus | - | - |
Trastuzumab Subcutaneous (SC) | Phase 2 | Cancer of Unknown Primary Site | - | - |
Peg-interferon alpha-2a, Ribavirin | Phase 2 | Chronic Hepatitis C | - | - |
RO4588161 | Phase 2 | Hepatitis C, Chronic | - | - |
Aromatase Inhibitor | Phase 2 | Breast Cancer | - | - |
Diphenhydramine hydrochloride (HCl) | Phase 2 | Lupus Nephritis | - | - |
IMM-101 | Phase 2 | Colorectal Cancer | - | - |
Peg-interféron alpha 2a + ribavirin | Phase 2 | Hepatitis | - | - |
Tocilizumab (Actemra®) | Phase 2 | Acute Hypoxemic Respiratory Failure | - | - |
Cytotoxic Combination | Phase 2 | Behcet's Syndrome | - | - |
Clindamycin in hydrocortisone lotion | Phase 2 | Rash | - | - |
Hormonal Therapy | Phase 2 | Breast Cancer | - | - |
Allogeneic islets of Langerhans transplant | Phase 2 | Type 1 Diabetes | - | - |
CAL-101 | Phase 2 | Chronic Lymphocytic Leucemia | - | - |
Mericitabine | Phase 2 | Hepatitis C | - | - |
fotemustine | Phase 2 | Glioblastoma Multiforme | - | - |
Induction Chemotherapy | Phase 2 | Breast Cancer | - | - |
gemcitabine, oxaliplatin, capecitabine | Phase 2 | Locally Advanced Pancreatic Cancer | - | - |
Tobemstomig | Phase 2 | Urothelial Cancer | - | - |
Ribavirin (drug) | Phase 2 | Hepatitis C, Chronic | - | - |
Interferon gamma (drug) | Phase 2 | Hepatitis C, Chronic | - | - |
Obinutuzumab and Pixantrone | Phase 2 | Lymphoma, Non-Hodgkin | - | - |
Actos | Phase 2 | Diabetes Mellitus Type 2 | - | - |
capecitabine (Xeloda) | Phase 2 | Rectal Cancer | - | - |
PHY906 | Phase 2 | Pancreatic Cancer | - | - |
Erythropoietin Beta | Phase 2 | Myelodysplastic Syndromes | - | - |
DOX: Docetaxel, oxaliplatin, Capecitabine | Phase 2 | Gastric Cancer | - | - |
Docetaxel, Leucovorin, Fluorouracil, Cisplatin | Phase 2 | Gastroesophageal Junction Adenocarcinoma | - | - |
Trastuzumab, Docetaxel, Bevacizumab | Phase 2 | Breast Cancer | - | - |
Rituximab + CHOP chemotherapy | Phase 2 | Primary Gastric Diffuse-Large B-Cell Lymphoma | - | - |
LABA | Phase 2 | Asthma | - | - |
Forimtamig | Phase 2 | Relapsed or Refractory Multiple Myeloma | - | - |
PEGPH20 | Phase 2 | Pancreatic Adenocarcinoma | - | - |
Induction- PF-06480605 | Phase 2 | Moderate to Severe Ulcerative Colitis | - | - |
RO4602522 | Phase 2 | Alzheimer's Disease | - | - |
RO5027838 | Phase 2 | Diabetes Mellitus Type 2 | - | - |
Zifibancimig | Phase 2 | Macular Degeneration | - | - |
GDC-4198 | Phase 2 | Breast Cancer | - | - |
Doxycline | Phase 2 | Non-Small Cell Lung Cancer | - | - |
RG1662 | Phase 2 | Down Syndrome | - | - |
obinutuzumab (RO5072759) | Phase 2 | Non-Hodgkin's Lymphoma | - | - |
Iberdomide | Phase 2 | Multiple Myeloma | - | - |
Enicepatide | Phase 2 | Overweight or Obese | - | - |
capecitabine (Xeloda®) | Phase 2 | Breast Cancer | - | - |
Standard platinum-based chemotherapy | Phase 2 | Non-Small Cell Lung Cancer | - | - |
bevacizumab (Avastin) | Phase 2 | Liver Cancer | - | - |
Emicizumab Injection | Phase 2 | Hemophilia A, Acquired | - | - |
Oxaliplatine | Phase 2 | Metastatic Colorectal Cancer | - | - |
Mosunetuzumab (SC) | Phase 2 | Follicular Lymphoma | - | - |
Vemurafenib plus Cobimetinib (combination) | Phase 2 | Cancer | - | - |
OSI-774 | Phase 2 | Pancreatic Cancer | - | - |
RO4876904 | Phase 2 | Diabetes Mellitus Type 2 | - | - |
Crenezumab | Phase 2 | Alzheimer Disease | - | - |
Obinutuzumab/Intravenous | Phase 2 | Follicular Lymphoma | - | - |
Samuraciclib | Phase 2 | Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer | - | - |
Trastuzumab deruxtecan | Phase 2 | HER2-positive Breast Cancer | - | - |
ANA598 | Phase 2 | HCV Infection | - | - |
Copegus | Phase 2 | Hepatitis C, Chronic | - | - |
N-acetylcysteine | Phase 2 | Idiopathic Pulmonary Fibrosis | - | - |
OpRegen | Phase 2 | Age-Related Macular Degeneration | - | - |
Olaparib+Bevacizumab to SCLC patients | Phase 2 | Lung Cancer | - | - |
Epidoxorubicin | Phase 2 | Breast Cancer | - | - |
RO7795081 | Phase 2 | Obesity or Overweight | - | - |
Pravastatin | Phase 2 | Dyslipidemia | - | - |
Orlistat | Phase 2 | Diabetes Mellitus | - | - |
Tumor samples analysis | Phase 2 | Triple Negative Breast Cancer | - | - |
Experimental | Phase 2 | Diabetic Neuropathy | - | - |
Docetaxel, Cisplatin, 5-FU and Cetuximab | Phase 2 | Nasopharyngeal Carcinoma | - | - |
Investigator's choice of anti-cancer treatment (except immunotherapy) | Phase 2 | Breast Cancer | - | - |
Atezolizumab plus Tiraglolumab | Phase 2 | Squamous Cell Carcinoma of the Anal Canal | - | - |
Association atezolizumab + BDB001 + RT | Phase 2 | Solid Tumor, Adult | - | - |
Taxane (docetaxel or paclitaxel) | Phase 2 | Breast Cancer | - | - |
RO5190591 | Phase 2 | Hepatitis C, Chronic | - | - |
Temozolomide (TMZ) | Phase 2 | High Grade Glioma | - | - |
5-FU, leucovorin, docetaxel, oxaliplatin (FLOT), trastuzumab | Phase 2 | Adenocarcinoma of the Gastroesophageal Junction | - | - |
RAR Gamma | Phase 2 | Emphysema | - | - |
Basmisanil | Phase 2 | Schizophrenia | - | - |
RG7774 | Phase 2 | Diabetic Retinopathy | - | - |
Immunochemotherapy | Phase 2 | Central Nervous System Lymphoma | - | - |
Chronic- PF-06480605 | Phase 2 | Moderate to Severe Ulcerative Colitis | - | - |
Rituximab and DexaBEAM | Phase 2 | Relapsed Non-Hodgkin-Lymphoma | - | - |
Chemotherapy (FOLFIRI regimen, FOLFOX regimen or LV5FU2 regimen) | Phase 2 | Colorectal Cancer | - | - |
BVZ+XELOX or BVZ+XELIRI or BVZ+FUIRI or BVZ+FUOX | Phase 2 | Colorectal Cancer | - | - |
Erlotinib + docetaxel | Phase 2 | Non Small Cell Lung Cancer | - | - |
Perjeta Injectable Product | Phase 2 | Breast Neoplasms | - | - |
Fosamprenavir | Phase 2 | HIV Infections | - | - |
Herceptin+XELOX | Phase 2 | Metastatic or Recurrent Gastric Adenocarcinoma | - | - |
Ocrelizumab Test Formulation | Phase 2 | Multiple Sclerosis | - | - |
Xeloda | Phase 2 | Breast Cancer | - | - |
Tocilizumab + Glucocorticoids (GCs) | Phase 2 | Giant Cell Arteritis | - | - |
C.E.R.A | Phase 2 | Anemia | - | - |
NXT007 | Phase 2 | Hemophilia A | - | - |
Mosunetuzumab (IV) | Phase 2 | B-cell Non-Hodgkin Lymphoma | - | - |
beta-lactam | Phase 2 | Soft Tissue Infections | - | - |
Atezolizumab in | Phase 2 | Extensive-stage Small Cell Lung Cancer | - | - |
Rituxumab | Phase 2 | B-cell Non-Hodgkin Lymphoma | - | - |
SOC Agent | Phase 2 | Glioblastoma | - | - |
Blood sample collection | Phase 2 | Squamous Cell Carcinoma of the Head and Neck | - | - |
Didanosine | Phase 2 | HIV Infections | - | - |
Folinic Acid | Phase 2 | Rectal Cancer | - | - |
Polatuzumab vedotin (Liquid) | Phase 2 | Lymphoma | - | - |
Autogene Cevumeran | Phase 2 | Muscle-invasive Urothelial Carcinoma | - | - |
Carboplatin/Cisplatin | Phase 2 | Nasopharyngeal Cancer | - | - |
Epothilone D | Phase 2 | Breast Cancer | - | - |
Pertuzumab and Trastuzumab Fixed-Dose Combination for Subcutaneous Administration (PH FDC SC) | Phase 2 | HER2-Positive Early Breast Cancer | - | - |
Interferon alfa-2a | Phase 2 | Renal Cell Cancer | - | - |
Interleukin 2 | Phase 2 | HIV Infections | - | - |
Folic Acid | Phase 2 | Rheumatoid Arthritis | - | - |
Endocrine therapy | Phase 2 | HER2-positive Breast Cancer | - | - |
GK Activator (2) | Phase 2 | Diabetes Mellitus Type 2 | - | - |
Atezolizumab & Bevacizumab | Phase 2 | Mesothelioma, Malignant | - | - |
Docetaxel, Capecitabine, Cisplatin, Bevacizumab | Phase 2 | Advanced Gastric Cancer | - | - |
Axitinib | Phase 2 | Renal Cell Carcinoma | - | - |
Diprosone | Phase 2 | Metastatic Colorectal Cancer | - | - |
Capecitabine+Irinotecan+Bevacizumab | Phase 2 | Metastatic Colorectal Cancer | - | - |
Atezolizumab (MPDL3280A) | Phase 2 | Lymphoma, Follicular | - | - |
lenalidomide, bendamustine, rituximab | Phase 2 | Mantle Cell Lymphoma | - | - |
R-EPOCH and cART | Phase 2 | Lymphoma, AIDS Related | - | - |
TCS Cream | Phase 2 | Atopic Dermatitis | - | - |
Pegylated interferon alfa-2a plus nucleos(t)ide(s) | Phase 2 | Chronic Hepatitis B | - | - |
DPP-IV Inhibitor | Phase 2 | Diabetes Mellitus Type 2 | - | - |
vismodegib | Phase 2 | Basal Cell Carcinoma | - | - |
SPK-8011QQ | Phase 2 | Hemophilia A | - | - |
PEGASYS [peginterferon alfa-2a] | Phase 2 | Hepatitis B, Chronic | - | - |
MSTT1041A | Phase 2 | Asthma | - | - |
Glofitamab + Obinutuzumab | Phase 2 | Richter Syndrome | - | - |
RO7017773 | Phase 2 | Autism Spectrum Disorder (ASD) | - | - |
RO 205-2349 | Phase 2 | Diabetes | - | - |
Danoprevir | Phase 2 | Hepatitis C, Chronic | - | - |
Tenofovir-Emtricitabine | Phase 2 | Leukoencephalopathy, Progressive Multifocal | - | - |
RO5024048 | Phase 2 | Hepatitis C, Chronic | - | - |
Olesoxime (TRO19622) | Phase 2 | Chemotherapy-Induced Peripheral Neuropathy | - | - |
RO7247669 | Phase 2 | Melanoma | - | - |
Tiragolumab and Atezolizumab IV FDC | Phase 2 | PD-L1-selected Solid Tumors | - | - |
RG7314 | Phase 2 | Autism Spectrum Disorder | - | - |
Tociliuzumab | Phase 2 | COVID-19 Pneumonia | - | - |
Gemcitabine+erlotinib | Phase 2 | Metastatic Pancreatic Cancer | - | - |
Pertuzumab + trastuzumab | Phase 2 | Elderly Metastatic Breast Cancer Population | - | - |
Dinutuximab Beta | Phase 2 | Neuroblastoma | - | - |
TCH | Phase 2 | Breast Cancer | - | - |
RO7126209 | Phase 2 | Alzheimers Disease | - | - |
Tominersen | Phase 2 | Huntington Disease | - | - |
FOLFIRI + cetuximab | Phase 2 | Colorectal Cancer Metastatic | - | - |
Obinutuzumab Injection | Phase 2 | Stage II Grade 1 Follicular Lymphoma | - | - |
PEG-IFN alfa-2a, Tenofovir | Phase 2 | Hepatitis D | - | - |
FEC | Phase 2 | Breast Cancer | - | - |
RO6889450 | Phase 2 | Schizophrenia, Schizoaffective Disorder | - | - |
RO4998452 | Phase 2 | Diabetes Mellitus Type 2 | - | - |
Atezolizumab and Radiotherapy | Phase 2 | Penile Cancer | - | - |
fluorouracil (5FU) | Phase 2 | Colorectal Cancer | - | - |
Bendamustine, Rituximab, Lenalidomide | Phase 2 | Chronic Lymphocytic Leukemia | - | - |
MPDL3280A | Phase 2 | Non-small Cell Lung Cancer | - | - |
Peg-interferon alpha 2a (drug) | Phase 2 | Hepatitis C, Chronic | - | - |
AT-527 | Phase 2 | COVID-19 | - | - |
Atezolizumab Injection | Phase 2 | Bladder Cancer | - | - |
RO5190591 (Danoprevir) | Phase 2 | Hepatitis C, Chronic | - | - |
SGN-LIV1A | Phase 2 | Metastatic Breast Cancer | - | - |
FOLFOX induction regimen | Phase 2 | Colorectal Cancer | - | - |
Carbo/cyclo | Phase 2 | Breast Cancer | - | - |
rituximab (anti-CD20) | Phase 2 | Sjogren's Syndrome | - | - |
First line chemotherapy | Phase 2 | Mantle Cell Lymphoma | - | - |
bevacizumab and trabectedin | Phase 2 | Ovarian Epithelial Cancer Recurrent | - | - |
GA101 | Phase 2 | Chronic Lymphocytic Leucemia | - | - |
RO4905417 | Phase 2 | Coronary Heart Disease, Graft Occlusion, Vascular | - | - |
SSRI | Phase 2 | Obsessive-Compulsive Disorder | - | - |
P38 Inhibitor (4) | Phase 2 | Rheumatoid Arthritis | - | - |
Ceftriaxone | Phase 2 | Pneumonia, Bacterial | - | - |
danoprevir + ritonavir | Phase 2 | Hepatitis C, Chronic | - | - |
Ribavirine | Phase 2 | Chronic Hepatitis C | - | - |
Mycophenolate Mofetil/Mycophenolic Acid | Phase 2 | Lupus Nephritis | - | - |
RO5313534 | Phase 2 | Alzheimer's Disease | - | - |
L-Leucovorin | Phase 2 | Metastatic Colorectal Cancer | - | - |
Balovaptan | Phase 2 | Stress Disorders, Post-Traumatic | - | - |
Carboplatin-based chemotherapy | Phase 2 | Non-Small Cell Lung Cancer | - | - |
Pegylated Interferon (Peginterferon) Alfa-2a | Phase 2 | Hepatitis B, Chronic | - | - |
Bendamustine and subcutaneous rituximab | Phase 2 | Aggressive Lymphoma | - | - |
Lomvastomig | Phase 2 | Advanced or Metastatic Esophageal Squamous Cell Carcinoma | - | - |
YL201 | Phase 2 | Thoracic Neoplasms, Lung Diseases, Small Cell Lung Carcinoma | - | - |
Standard taxane therapy | Phase 2 | Breast Cancer | - | - |
RG3421 | Phase 2 | Psoriasis | - | - |
2-CdA | Phase 2 | Lymphoma of Mucosa-Associated Lymphoid Tissue | - | - |
GC33 | Phase 2 | Carcinoma, Hepatocellular | - | - |
Nucleos(t)ide (NUC) | Phase 2 | Hepatitis B, Chronic | - | - |
Mosunetuzumab is a bispecific monoclonal antibody targeting CD20 on B cells and CD3 on T cells, redirecting T cells to eliminate malignant B cells | Phase 2 | Follicular Lymphoma | - | - |
Ibrutinib/Bortezomib/Rituximab | Phase 2 | Waldenstrom Macroglobulinemia | - | - |
pralsetinib (BLU-667) | Phase 2 | RET-altered Non Small Cell Lung Cancer | - | - |
Trastuzumab+Docetaxel+NPLD | Phase 2 | Breast Cancer | - | - |
setrobuvir | Phase 2 | Hepatitis C, Chronic | - | - |
Polyenylphosphatidylcholine (PPC) | Phase 2 | Hepatitis C | - | - |
Topical clindamycin, triamcinolone acetonide soln | Phase 2 | Rash | - | - |
eloxatin | Phase 2 | Colorectal Cancer | - | - |
Trastuzumab+Docetaxel+NPLD+Bevacizumab | Phase 2 | Breast Cancer | - | - |
Myocet | Phase 2 | Breast Cancer | - | - |
docetaxel, capecitabine | Phase 2 | Metastatic Breast Cancer | - | - |
Bevacizumab + Capecitabine + Radiotherapy | Phase 2 | Rectal Cancer | - | - |
preoperative induction chemotherapy in combination with bevacizumab followed by combined radiochemotherapy with capecitabine | Phase 2 | Rectal Cancer | - | - |
RO4917523 | Phase 2 | Fragile X Syndrome | - | - |
Trastuzumab and Pertuzumab (FDC SC) and T-DM1 | Phase 2 | Early Breast Cancer | - | - |
Erlotinib, escalating dose | Phase 2 | Pancreatic Cancer | - | - |
Inhaled corticposteroids (ICS) | Phase 2 | Asthma | - | - |
Pertuzumab, trastuzumab | Phase 2 | Esophageal Carcinoma | - | - |
RO4995819 | Phase 2 | Major Depressive Disorder | - | - |
Optimized Background ARVs | Phase 2 | HIV Infections | - | - |
Abacavir sulfate | Phase 2 | HIV Infections | - | - |
Tarceva (OSI-774) | Phase 2 | Colorectal Cancer | - | - |
RO5459072 | Phase 2 | Sjogren's Syndrome | - | - |
Alogabat | Phase 2 | Angelman Syndrome | - | - |
89Zr-Df-IAB22M2C | Phase 2 | Non-Hodgkins Lymphoma | - | - |
Atezolizumab and Bevacizumab | Phase 2 | Cancer | - | - |
RO5185426 | Phase 2 | Malignant Melanoma | - | - |
Mosunetuzumab Intravenous (IV) | Phase 2 | Diffuse Large B-cell Lymphoma | - | - |
ADG126 | Phase 2 | Advanced Liver Cancers | - | - |
Breast Cancer
3 drugs in this indication
Alzheimer's disease
3 drugs in this indication
Huntington's disease
2 drugs in this indication
oncology
2 drugs in this indication
neovascular age-related macular degeneration (nAMD)
2 drugs in this indication
Obesity
2 drugs in this indication
thyroid eye disease
2 drugs in this indication
Haematological Malignancy
2 drugs in this indication
Tuberculosis infection (latent TB) identification
1 drug in this indication
dMMR/MSI-H metastatic colorectal cancer
1 drug in this indication
Unresectable Hepatocellular Carcinoma
1 drug in this indication
Paroxysmal Nocturnal Hemoglobinuria
1 drug in this indication
advanced hepatocellular carcinoma
1 drug in this indication
Non-Small Cell Lung Cancer
1 drug in this indication
Humoral Rejection in Kidney Transplantation
1 drug in this indication
muscle-invasive bladder cancer
1 drug in this indication
cyclospora detection
1 drug in this indication
Hepatitis D detection
1 drug in this indication
relapsed small-cell lung cancer
1 drug in this indication
Inflammation & Immunology diseases
1 drug in this indication
adjuvant treatment of stage III colon cancer
1 drug in this indication
Adjuvant treatment of resected stage III dMMR or MSI-H colon cancer
1 drug in this indication
relapsing multiple sclerosis in children and adolescents
1 drug in this indication
slow-growing type of blood cancer (lymphoma)
1 drug in this indication
Follicular lymphoma
1 drug in this indication
adjuvant treatment of stage III deficient DNA mismatch repair (dMMR) colon cancer
1 drug in this indication
relapsing forms of multiple sclerosis in pediatric patients aged 10 years and older
1 drug in this indication
Malaria detection
1 drug in this indication
Adjuvant treatment of Stage III colon cancer in combination with fluoropyrimidine and oxaliplatin
1 drug in this indication
lupus
1 drug in this indication
weight loss
1 drug in this indication
Duchenne Muscular Dystrophy
1 drug in this indication
ADC-resistant cancers
1 drug in this indication
Bacterial vaginosis and Candida vaginitis diagnosis
1 drug in this indication
polypoidal choroidal vasculopathy (PCV), a sub-type of neovascular age-related macular degeneration (nAMD)
1 drug in this indication
myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD)
1 drug in this indication
lung cancer
1 drug in this indication
HER2-positive breast cancer
1 drug in this indication
Zika virus RNA screening in donor samples
1 drug in this indication
Asthma
1 drug in this indication
Malignant Pleural Mesothelioma
1 drug in this indication
influenza
1 drug in this indication
Myasthenia Gravis Generalised
1 drug in this indication
relapsed or refractory follicular lymphoma
1 drug in this indication
Stage III colon cancer
1 drug in this indication
Bullous Pemphigoid
1 drug in this indication
dMMR colon cancer
1 drug in this indication
thyroid eye disease (TED)
1 drug in this indication
Breast Neoplasms
1 drug in this indication
Metastatic Colorectal Cancer
1 drug in this indication
off-the-shelf CAR T (indication not specified)
1 drug in this indication
IgA nephropathy (IgAN)
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Roche Holding AG's drug pipeline?→
CatalystAlert tracks 538 drug candidates in Roche Holding AG's (RHHBY) pipeline across Phase 3, Phase 2. Its lead program is Obinutuzumab/Intravenous (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Roche Holding AG's next FDA catalyst?→
Roche Holding AG's (RHHBY) next tracked catalyst is a PDUFA date expected Nov 30, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track RHHBY biotech catalysts?→
Add RHHBY to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Roche Holding AG's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.